Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-07-23Clinical Trial Update: Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM [NA]
A recruiting study is evaluating the safety and efficacy of Anti-BCMA-GPRC5D CAR-T cell therapy for relapsed/refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients [Phase 3]
This entry reports the completion of a Phase 3 randomized trial comparing lenalidomide, melphalan, and prednisone versus high-dose melphalan…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS [Phase 3]
Phase 3 clinical trial comparing a standard dosing schedule to a new dose-reduction algorithm in elderly and unfit newly diagnosed multiple …
-
CLINICAL_TRIALS other · 2024-07-17Clinical Trial Update: Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients [Phase 2]
A Phase 2 clinical trial evaluating bispecific T-cell redirectors as first-line therapy for transplant-eligible multiple myeloma is currentl…
-
CLINICAL_TRIALS trial_result · 2024-07-16Clinical Trial Update: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma [Phase 2]
A Phase 2 clinical trial update reports results of a quadruplet regimen combining daratumumab, carfilzomib, lenalidomide, and dexamethasone …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-07-16Clinical Trial Update: Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating nanobody-based Biepitope CAR-T cells targeting BCMA for relapsed/refractory multiple myeloma. The stud…
-
CLINICAL_TRIALS withdrawal · 2024-07-16Clinical Trial Update: Marizomib Central Nervous System (CNS) [Phase 2]
A Phase 2 trial of marizomib for multiple myeloma (including relapsed disease) has been withdrawn.
-
CLINICAL_TRIALS research · 2024-07-15Clinical Trial Update: A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma [Phase 1]
A Phase 1 study evaluating QLS4131 for relapsed or refractory multiple myeloma, currently not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-07-12Clinical Trial Update: Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma [Phase 2]
Results from a Phase 2 trial of the panobinostat, bortezomib, and dexamethasone combination in relapsed or relapsed-and-refractory multiple …
-
CLINICAL_TRIALS research · 2024-07-12Clinical Trial Update: Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer [Phase 2]
Phase 2 clinical trial evaluating curcumin and piperine in patients under surveillance for monoclonal gammopathy, smoldering multiple myelom…
-
CLINICAL_TRIALS trial_result · 2024-07-11Clinical Trial Update: Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma [Phase 1]
DCR-MYC, an investigational therapy, was evaluated in a Phase I multicenter dose-escalation study in patients with solid tumors, multiple my…
-
CLINICAL_TRIALS withdrawal · 2024-07-10Clinical Trial Update: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant [Phase 2]
This update reports the withdrawal of a Phase 2 trial evaluating selinexor plus lenalidomide as consolidation and maintenance after stem cel…
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma [Phase 1]
Phase 1 clinical trial update on ACY-241 given alone or in combination with pomalidomide and dexamethasone in multiple myeloma; the study st…
-
CLINICAL_TRIALS trial_result · 2024-07-09Clinical Trial Update: GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies [Phase 1, Phase 2]
GIC-102, an intravenously administered allogeneic NK cell therapy, is being evaluated in Phase 1/Phase 2 trials for advanced solid tumors an…
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients [Phase 2]
A Phase 2 clinical trial is investigating treosulfan (Trecondi Ideogen) in patients with multiple myeloma, and the study is currently recrui…
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) [Phase 2]
Phase 2 clinical trial PRONTO studies prophylactic versus on-demand use of tocilizumab, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-07-08Clinical Trial Update: A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice
This completed clinical trial studied how the duration of treatment relates to patient response in real-world cases of multiple myeloma or l…
-
CLINICAL_TRIALS research · 2024-07-05Clinical Trial Update: A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
This clinical trial update describes a perspective study evaluating MRD-tailored therapy for patients with newly diagnosed multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Precision Medicine for Patients With Identified Actionable Mutations [Phase 2]
A Phase 2 precision medicine trial for patients with identified actionable mutations in solid tumors, lymphoma, and multiple myeloma was ter…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Oral ONC201 in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating oral ONC201 in relapsed/refractory multiple myeloma was terminated, with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma [Phase 1]
Phase 1 study evaluating escalating doses of RO7297089 to assess safety and pharmacokinetics in patients with relapsed or refractory multipl…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma
A Travera Inc.-sponsored study evaluated Mass Accumulation Rate as a predictive biomarker in relapsed multiple myeloma; the trial has been t…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 trial TJ202 evaluating lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone in relapsed or refractory multiple mye…
-
CLINICAL_TRIALS research · 2024-07-03Clinical Trial Update: Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
ClinicalTrials.gov update shows ongoing recruitment for a study titled 'Living With a Myeloma in West-Occitanie' focusing on patients with m…
-
CLINICAL_TRIALS withdrawal · 2024-07-03Clinical Trial Update: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy [Phase 2]
A Phase 2 trial evaluating pembrolizumab as salvage therapy for plasma cell myeloma patients progressing after CAR-T therapy has been withdr…